Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tacrolimus
Drug ID BADD_D02105
Description Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condition vitiligo. It was discovered in 1984 from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis. Tacrolimus is chemically known as a macrolide. It reduces peptidyl-prolyl isomerase activity by binding to the immunophilin FKBP-12 (FK506 binding protein) creating a new complex. This FKBP12-FK506 complex inhibits calcineurin which inhibits T-lymphocyte signal transduction and IL-2 transcription.
Indications and Usage For use after allogenic organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It was given FDA approval in 1994 for use in liver transplantation. Since then, this indication has expanded to kidney, heart, small bowel, pancreas, lung, trachea, skin, cornea, and limb transplants. It has also been used in a topical preparation in the treatment of severe atopic dermatitis.
Marketing Status approved; investigational
ATC Code D11AH01; L04AD02
DrugBank ID DB00864
KEGG ID D00107; D08556
MeSH ID D016559
PubChem ID 445643
TTD Drug ID D06OMK
NDC Product Code 0904-6623; 51927-0092; 65897-3010; 68254-0020; 73377-010; 16729-041; 16729-421; 0093-3428; 63629-8726; 0378-2045; 67877-279; 67877-280; 68254-5006; 68992-3010; 68992-3075; 0469-1230; 70518-3216; 38779-2698; 47848-018; 49629-020; 51187-0006; 65050-0321; 68254-2502; 0093-3429; 43817-421; 50222-211; 55111-527; 63629-9325; 64380-721; 0378-2047; 68084-450; 68308-703; 70518-2996; 0904-6624; 0168-0416; 45802-390; 45802-700; 51079-028; 51079-818; 55111-526; 68462-686; 0469-0607; 70748-221; 60429-378; 68254-5005; 68462-534; 70377-014; 70748-220; 65897-1010; 16714-100; 0378-2046; 67877-278; 68462-687; 70377-015; 70518-3388; 49629-022; 52076-6222; 16729-042; 16729-422; 51079-817; 68084-449; 0469-1330; 69452-154; 69452-155; 72572-761; 82983-401; 82983-402; 16714-098; 55111-525; 60429-379; 63629-8725; 68084-451; 0469-0657; 71335-2189; 72572-760; 49629-021; 52928-006; 62991-3072; 50090-5596; 50222-203; 54288-135; 55154-4168; 68254-5004; 0469-0617; 0469-3016; 0781-2102; 0781-2103; 82983-400; 0168-0417; 43817-423; 55154-4080; 60429-377; 68992-3040; 70377-016; 82160-124; 55500-0010; 65727-009; 68254-0002; 43353-317; 43817-422; 62250-665; 63629-8723; 64380-720; 64380-722; 68462-685; 69452-153; 70748-219; 0781-2104; 0904-7097; 51552-1403; 52972-0040; 55486-1576; 16714-099; 16729-043
UNII WM0HAQ4WNM
Synonyms Tacrolimus | Prograf | Prograft | FR-900506 | FR 900506 | FR900506 | Anhydrous Tacrolimus | Tacrolimus, Anhydrous | Tacrolimus Anhydrous | Anhydrous, Tacrolimus | FK-506 | FK 506 | FK506
Chemical Information
Molecular Formula C44H69NO12
CAS Registry Number 104987-11-3
SMILES CC1CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC(=O)C(C=C(C1)C)CC=C)O)C)C(=CC 4CCC(C(C4)OC)O)C)O)C)OC)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Liver transplant rejection12.02.03.011; 10.02.03.005; 09.01.08.0070.008169%Not Available
Loss of consciousness17.02.04.004--Not Available
Lung consolidation22.01.02.0100.000743%Not Available
Lung disorder22.02.07.001--Not Available
Lung infiltration22.01.02.0040.000446%Not Available
Lymphadenopathy01.09.01.0020.004515%Not Available
Lymphoedema24.09.01.001; 01.09.01.0060.000297%
Lymphoma16.20.01.001; 01.12.01.0010.001782%Not Available
Macular degeneration06.09.03.0010.001248%Not Available
Maculopathy06.09.03.0070.001634%Not Available
Malabsorption14.02.01.004; 07.17.01.0010.000297%
Malaise08.01.01.003--
Malignant melanoma23.08.01.001; 16.03.01.0010.000891%Not Available
Mass08.03.05.0030.000594%Not Available
Megacolon07.02.05.0020.000891%Not Available
Melanocytic naevus23.10.01.007; 16.26.01.0070.001248%Not Available
Memory impairment17.03.02.003; 19.20.01.003--
Menopausal symptoms21.02.02.002--Not Available
Mental disability26.01.01.001--Not Available
Metabolic acidosis14.01.01.0030.006089%Not Available
Metastases to lung22.08.01.005; 16.22.02.0020.001782%Not Available
Metastatic malignant melanoma23.08.01.002; 16.03.01.0020.000891%Not Available
Microangiopathic haemolytic anaemia24.03.02.019; 01.06.02.0020.000743%Not Available
Micturition disorder20.02.02.005--Not Available
Migraine24.03.05.003; 17.14.02.0010.007040%Not Available
Mitral valve incompetence02.07.01.0020.001040%Not Available
Monoparesis17.01.04.011--Not Available
Monoplegia17.01.04.0030.000297%Not Available
Mood swings19.04.03.001--Not Available
Mouth ulceration07.05.06.004--Not Available
The 16th Page    First    Pre   16 17 18 19 20    Next   Last    Total 41 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene